Abstract: The invention relates to a novel enzyme involved in the biosynthesis of mycolic acids and to the use thereof for the screening of antibiotics, especially antimycobacterials. The invention more particularly relates to the Pks13 protein which catalyzes Claisen condensation or malonic condensation in mycolates between an acyl-CoA molecule or an acyl-AMP molecule and an acylmalonyl-CoA molecule to form an intermediate ?-cEto acyl or ?-cEto ester.

Abstract: The protein MabA, also named protein FabG1, which is recombinant in a purified form, or the recombinant proteins derived from the protein MabA by mutation of at least one amino acid. The uses of proteins MabA, or recombinant proteins derived from protein MabA by mutation of at lease one amino acid, proteins and to the crystalloghraphis co-ordinates thereof, in terms of the implementation of methods for designing and screening ligands of these proteins, and advantageously, ligands inhibiting the enzymatic activity of these proteins.

Abstract: The invention relates to (3R)-hydroxyacyl-ACP dehydratase enzymes involved in the biosynthesis of mycolic acids, and to the use of same for screening antibiotics, medicaments that can be used to treat infections in humans or in animals, caused by Corynebacterineae, more specifically infections caused by pathogenic mycobacteria (Mycobacterium tuberculosis, M. africanum, M. leprae, M. ulcerans, M. microti, M. bovis, M. abscissus, M. avium, M. fortuitum, M. kansasii . . . ), and infections caused by other genera such as Nocardia, Rhodococcus, Gordona . . .

Abstract: The main subject of the present invention is the use of complexes of NADP with the protein MabA, or with a derived protein, and more particularly the crystallographic coordinates of these proteins in the frame of said complexes, within the framework of the implementation of methods for designing and screening ligands of these proteins, and advantageously ligands inhibiting the enzymatic activity of these proteins, namely antibiotics capable of being used within the framework of the treatment of mycobacteriosis.

Abstract: The invention relates to a novel enzyme involved in the biosynthesis of mycolic acids and to the use thereof for the screening of antibiotics, especially antimycobacterials. The invention more particularly relates to the Pks13 protein which catalyzes Claisen condensation or malonic condensation in mycolates between an acyl-CoA molecule or an acyl-AMP molecule and an acylmalonyl-CoA molecule to form an intermediate ?-cEto acyl or ?-cEto ester.

Abstract: The invention especially relates to the protein MabA, also named protein FabG1, which is recombinant in a purified form, or the recombinant proteins derived from the protein MabA by mutation of at least one amino acid. The invention also relates to the uses of said proteins and to the crystallographic co-ordinates thereof, in terms of the implementation of methods for designing and screening ligands of said proteins, and advantageously, ligands inhibiting the enzymatic activity of said proteins.

Abstract: The invention concerns a method for detecting and/or quantifying Mycobacterium tuberculosis in a sample, characterised in that it consists in detecting in said sample the presence of an intein inserted at a site whereof the location is Mycobacterium tuberculosis specific using a reagent specific to said location, and optionally in quantifying the detected signal.